TARGETING THE CHK1-STAT3-CIP2A AXIS TO TREAT GLIOBLASTOMA (GBM)

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1090035

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Glioblastoma (GBM is a high-grade brain tumour for which current treatments are inadequate. Tumour recurrence is almost inevitable and average life expectancy is measured in months. We have identified a DNA-damage signalling pathway and demonstrated that perturbation of the pathway significantly reduces tumour growth. We plan to target key proteins of the recently identified pathway and validate these findings using tumour cells directly from GBM patients and relevant animal models of human GBM.

Funded Activity Details

Start Date: 01-01-2015

End Date: 01-01-2019

Funding Scheme: Early Career Fellowships

Funding Amount: $321,048.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

DNA damage | carcinogenesis | glioblastoma | prognostic markers | therapeutic target

Related Links